A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention

2020167 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov: NCT03238781.

Good health and well-being

Published in: Cephalalgia

Volume 41, Issue 1, pp. 33-44

Field-Weighted Citation Impact: 9.38